Genitourinary Cancers | Specialty

Kidney Cancer: Continuing to Improve Survival

July 17th 2017

Understanding the Biology of Kidney Cancer

July 17th 2017

Experts Discuss Immunotherapy's Evolution in Bladder Cancer

July 15th 2017

The explosion of new checkpoint immunotherapy drugs has changed the paradigm of care for patients with urothelial carcinoma, the most common form of bladder cancer.

ODAC Unanimously Supports Bevacizumab Biosimilar ABP-215

July 13th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 17-0 to recommend approval for ABP-215, a biosimilar for bevacizumab (Avastin) to treat a range of solid tumors.

Dr. Petrylak on Combinations with Pembrolizumab in Urothelial Carcinoma

July 13th 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses combinations with pembrolizumab (Keytruda) for patients with urothelial carcinoma.

Dr. Chowdhury on Separate Roles of Pazopanib and Pembrolizumab in RCC

July 12th 2017

Simon Chowdhury, MA, MBBS, MRCP, PhD, consultant medical oncologist specializing in urological cancer, Sarah Cannon Research Institute, United Kingdom, discusses what roles pazopanib (Votrient) and pembrolizumab (Keytruda) have as monotherapy for patients with renal cell carcinoma (RCC).

Published Ipilimumab/Nivolumab Data Highlight Activity in Metastatic RCC

July 12th 2017

Patients with metastatic renal cell carcinoma had an objective response rate of 40% and a 2-year overall survival rate of nearly 70% with the immune checkpoint combination of ipilimumab (Yervoy) and nivolumab (Opdivo), in phase I results from CheckMate-016.

Dr. Balar on the Approval of Pembrolizumab for Bladder Cancer

July 11th 2017

Arjun V. Balar, MD, assistant professor of medicine, Division of Hematology and Oncology, New York University Cancer Institute, NYU Langone Medical Center, discusses the approval of pembrolizumab (Keytruda) in bladder cancer.

Dr. Garcia on Sequencing Immunotherapies in Bladder Cancer

July 11th 2017

Jorge Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the optimal sequence of immunotherapies for the treatment of patients with bladder cancer.

Expert Discusses Rapid Evolution of RCC Treatment

July 10th 2017

Shilpa Gupta, MD, MBBS, discusses the future of drug therapies for kidney cancer, and the challenges facing the research landscape.

Management of Bilateral and Multifocal RCC: Family Matters

July 7th 2017

Gennaday Bratslavsky, MD, discusses the evaluation and management of RCC and highlighted genetic testing for the patient’s family.

Dr. Apolo on the Combination of Cabozantinib Plus Nivolumab in Urothelial Carcinoma

July 7th 2017

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the combination of cabozantinib (Cabometyx) plus nivolumab (Opdivo) in patients with urothelial carcinoma.

Dr. Rini on Adjuvant Immunotherapy in Renal Cell Carcinoma

July 6th 2017

Brian I. Rini, MD, professor of medicine, Cleveland Clinic, discusses the potential of immunotherapy as an adjuvant treatment for patients with renal cell carcinoma (RCC).

It's a Family Affair

July 3rd 2017

The vision and dedication to training future urologic surgeons and advancing care by these giants of urology should never go unrecognized, underappreciated, or forgotten.

Rini Highlights Mixed Findings on Adjuvant Kidney Cancer Data

June 29th 2017

Brian Rini, MD, discusses additional adjuvant trials that have perplexed the field, what potential immunotherapy could have in this setting, and other obstacles to tackle in the renal cell carcinoma landscape.

Dr. Atkins on Results of Atezolizumab Plus Bevacizumab in RCC

June 29th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses the results of a trial of atezolizumab (Tecentriq) plus bevacizumab (Avastin) in renal cell carcinoma.

Future of Immunotherapy for GU Malignancies Goes Beyond Oncology Department

June 28th 2017

Costas Lallas, MD, discusses the current role of immunotherapy for patients with genitourinary cancers, the potential for immunotherapy in combination with chemotherapy, and how the rise of immunotherapy affects all providers treating patients with these malignancies.

Dr. Apolo on Side Effects of Cabozantinib Plus Immunotherapy Agents in Bladder Cancer

June 28th 2017

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the side effects of cabozantinib (Cabometyx) plus immunotherapy agents in bladder cancer.

Update Sustains Frontline Pembrolizumab Benefit in Urothelial Carcinoma

June 26th 2017

Updated phase II results from the KEYNOTE-052 trial showed that first-line treatment with pembrolizumab (Keytruda) produced a long-lasting response for patients with cisplatin-ineligible advanced urothelial cancer.

Expert Addresses Advances and Challenges With Immunotherapy in RCC

June 26th 2017

Moshe Ornstein, MD, discusses the obstacles physicians are facing with the use of immunotherapy for patients with renal cell carcinoma.